1. Home
  2. LUNG vs JCE Comparison

LUNG vs JCE Comparison

Compare LUNG & JCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LUNG
  • JCE
  • Stock Information
  • Founded
  • LUNG 1995
  • JCE 2007
  • Country
  • LUNG United States
  • JCE United States
  • Employees
  • LUNG N/A
  • JCE N/A
  • Industry
  • LUNG Industrial Specialties
  • JCE Trusts Except Educational Religious and Charitable
  • Sector
  • LUNG Health Care
  • JCE Finance
  • Exchange
  • LUNG Nasdaq
  • JCE Nasdaq
  • Market Cap
  • LUNG 124.0M
  • JCE 253.3M
  • IPO Year
  • LUNG 2020
  • JCE N/A
  • Fundamental
  • Price
  • LUNG $2.78
  • JCE $15.46
  • Analyst Decision
  • LUNG Buy
  • JCE
  • Analyst Count
  • LUNG 6
  • JCE 0
  • Target Price
  • LUNG $11.53
  • JCE N/A
  • AVG Volume (30 Days)
  • LUNG 311.3K
  • JCE 49.7K
  • Earning Date
  • LUNG 07-30-2025
  • JCE 01-01-0001
  • Dividend Yield
  • LUNG N/A
  • JCE 9.26%
  • EPS Growth
  • LUNG N/A
  • JCE N/A
  • EPS
  • LUNG N/A
  • JCE N/A
  • Revenue
  • LUNG $87,473,000.00
  • JCE N/A
  • Revenue This Year
  • LUNG $18.02
  • JCE N/A
  • Revenue Next Year
  • LUNG $18.17
  • JCE N/A
  • P/E Ratio
  • LUNG N/A
  • JCE N/A
  • Revenue Growth
  • LUNG 19.84
  • JCE N/A
  • 52 Week Low
  • LUNG $2.50
  • JCE $11.64
  • 52 Week High
  • LUNG $9.37
  • JCE $14.28
  • Technical
  • Relative Strength Index (RSI)
  • LUNG 41.83
  • JCE 64.08
  • Support Level
  • LUNG $2.52
  • JCE $14.36
  • Resistance Level
  • LUNG $2.84
  • JCE $15.55
  • Average True Range (ATR)
  • LUNG 0.16
  • JCE 0.26
  • MACD
  • LUNG 0.04
  • JCE 0.05
  • Stochastic Oscillator
  • LUNG 46.36
  • JCE 93.28

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

About JCE Nuveen Core Equity Alpha Fund of Beneficial Interest

Nuveen Core Equity Alpha Fund is a diversified closed-end management investment company. Its investment objective is to provide an attractive level of total return, through long-term capital appreciation and through income and gains. The Fund invests in a portfolio of actively managed large-capitalization U.S. common stocks, using the sub-adviser's proprietary quantitative process designed to provide the potential for long-term outperformance. Additionally, the Fund seeks to reduce the volatility of its returns relative to the returns of the Equity Portfolio over extended periods by writing (selling) index call options and/or call options on custom baskets of securities.

Share on Social Networks: